Trials / Recruiting
RecruitingNCT06314529
Long-term Follow-up Study of BHC001 for TDT
Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 6 (estimated)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 5 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Detailed description
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Assessments | Safety and efficacy assessments |
Timeline
- Start date
- 2022-12-14
- Primary completion
- 2036-12-10
- Completion
- 2037-05-10
- First posted
- 2024-03-18
- Last updated
- 2024-03-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06314529. Inclusion in this directory is not an endorsement.